ATE461200T1 - Inhibitoren von cysteinprotease - Google Patents
Inhibitoren von cysteinproteaseInfo
- Publication number
- ATE461200T1 ATE461200T1 AT05702148T AT05702148T ATE461200T1 AT E461200 T1 ATE461200 T1 AT E461200T1 AT 05702148 T AT05702148 T AT 05702148T AT 05702148 T AT05702148 T AT 05702148T AT E461200 T1 ATE461200 T1 AT E461200T1
- Authority
- AT
- Austria
- Prior art keywords
- protease inhibitors
- cystein protease
- cystein
- inhibitors
- protease
- Prior art date
Links
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0400022A SE0400022D0 (sv) | 2004-01-08 | 2004-01-08 | New compounds |
| SE0401332A SE0401332D0 (sv) | 2004-05-26 | 2004-05-26 | New compounds |
| PCT/GB2005/050003 WO2005066180A1 (en) | 2004-01-08 | 2005-01-06 | Cysteine protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE461200T1 true ATE461200T1 (de) | 2010-04-15 |
Family
ID=34752290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05702148T ATE461200T1 (de) | 2004-01-08 | 2005-01-06 | Inhibitoren von cysteinprotease |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7915300B2 (de) |
| EP (1) | EP1701960B1 (de) |
| JP (1) | JP4787765B2 (de) |
| AR (1) | AR047373A1 (de) |
| AT (1) | ATE461200T1 (de) |
| AU (1) | AU2005203972B2 (de) |
| BR (1) | BRPI0506719A (de) |
| CA (1) | CA2552739A1 (de) |
| DE (1) | DE602005019971D1 (de) |
| ES (1) | ES2341869T3 (de) |
| TW (1) | TWI343384B (de) |
| WO (1) | WO2005066180A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7915300B2 (en) | 2004-01-08 | 2011-03-29 | Medivir Ab | Cysteine protease inhibitors |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| JP2008506702A (ja) | 2004-07-14 | 2008-03-06 | ピーティーシー セラピューティクス,インコーポレーテッド | C型肝炎を治療するための方法 |
| NZ553329A (en) | 2004-07-22 | 2010-09-30 | Ptc Therapeutics Inc | Thienopyridines for treating hepatitis C |
| GB0513840D0 (en) * | 2005-07-07 | 2005-08-10 | Medivir Ab | Cysteine protease inhibitors |
| GB0517279D0 (en) * | 2005-08-23 | 2005-10-05 | Amura Therapeutics Ltd | Biologically active compounds |
| US7947707B2 (en) * | 2005-10-07 | 2011-05-24 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| GB0611654D0 (en) * | 2006-06-13 | 2006-07-19 | Medivir Ab | Compounds |
| GB0614042D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614044D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614046D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614053D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614052D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614037D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614073D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0618263D0 (en) * | 2006-09-18 | 2006-10-25 | Medivir Ab | Compound |
| WO2008114054A1 (en) * | 2007-03-19 | 2008-09-25 | Medivir Ab | Protease inhibitors |
| US20110092484A1 (en) | 2007-06-08 | 2011-04-21 | Nippon Chemiphar Co., Ltd. | Therapeutic or prophylactic agent for cerebral aneurysm |
| US7893067B2 (en) * | 2007-06-27 | 2011-02-22 | Medivir Ab | Cysteine protease inhibitors |
| EP2786993B1 (de) | 2007-08-13 | 2017-11-15 | Monsanto Technology LLC | Zusammensetzungen und Verfahren zur Kontrolle von Nematoden |
| JPWO2009054454A1 (ja) | 2007-10-24 | 2011-03-03 | 国立大学法人 東京医科歯科大学 | カテプシン阻害剤を有効成分として含有するToll様受容体のシグナル伝達の調整剤 |
| WO2009087379A2 (en) * | 2008-01-09 | 2009-07-16 | Amura Therapeutics Limited | Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases |
| GB0804701D0 (en) | 2008-03-13 | 2008-04-16 | Amura Therapeutics Ltd | Compounds |
| GB0817424D0 (en) | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
| GB0916608D0 (en) | 2009-09-22 | 2009-11-04 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US10087190B1 (en) * | 2017-04-24 | 2018-10-02 | Purdue Research Foundation | Lactones |
| US10995803B2 (en) | 2018-12-04 | 2021-05-04 | Means Industries, Inc. | Electromagnetic system for controlling the operating mode of a non friction coupling assembly and coupling and magnetic control assembly having same |
| WO2022147694A1 (en) * | 2021-01-06 | 2022-07-14 | Beijing Erai Therapeutics Co., Ltd. | Aminoheteroaryl compounds and uses thereof |
| EP4613273A1 (de) | 2024-03-06 | 2025-09-10 | Vetbiolix | Behandlung von knochenschwund |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013079A1 (es) * | 1997-05-06 | 2000-12-13 | Smithkline Beecham Corp | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios |
| GB0003111D0 (en) | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
| CA2429001A1 (en) | 2000-11-17 | 2002-11-07 | Medivir Ab | Cysteine protease inhibitors |
| NZ526913A (en) | 2001-01-17 | 2004-12-24 | Amura Therapeutics Ltd | Inhibitors of cruzipain and other cysteine proteases |
| JP2003183161A (ja) * | 2001-12-21 | 2003-07-03 | Kitasato Inst:The | 骨粗鬆症の予防治療剤 |
| CA2548600A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| US20080200975A1 (en) | 2004-01-06 | 2008-08-21 | Nicast Ltd. | Vascular Prosthesis with Anastomotic Member |
| JP2007517810A (ja) | 2004-01-08 | 2007-07-05 | メルク フロスト カナダ リミテツド | カテプシンシステインプロテアーゼ阻害剤 |
| US7915300B2 (en) | 2004-01-08 | 2011-03-29 | Medivir Ab | Cysteine protease inhibitors |
| GB0513839D0 (en) | 2005-07-07 | 2005-08-10 | Medivir Ab | Cysteine protease inhibitors |
| GB0614052D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
-
2005
- 2005-01-06 US US10/584,930 patent/US7915300B2/en active Active
- 2005-01-06 CA CA002552739A patent/CA2552739A1/en not_active Abandoned
- 2005-01-06 AU AU2005203972A patent/AU2005203972B2/en not_active Ceased
- 2005-01-06 JP JP2006548412A patent/JP4787765B2/ja not_active Expired - Fee Related
- 2005-01-06 EP EP05702148A patent/EP1701960B1/de not_active Expired - Lifetime
- 2005-01-06 DE DE602005019971T patent/DE602005019971D1/de not_active Expired - Lifetime
- 2005-01-06 ES ES05702148T patent/ES2341869T3/es not_active Expired - Lifetime
- 2005-01-06 BR BRPI0506719-7A patent/BRPI0506719A/pt not_active IP Right Cessation
- 2005-01-06 WO PCT/GB2005/050003 patent/WO2005066180A1/en not_active Ceased
- 2005-01-06 AT AT05702148T patent/ATE461200T1/de not_active IP Right Cessation
- 2005-01-07 TW TW094100535A patent/TWI343384B/zh not_active IP Right Cessation
- 2005-01-07 AR ARP050100055A patent/AR047373A1/es not_active Application Discontinuation
-
2011
- 2011-01-19 US US13/009,773 patent/US20110112089A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR047373A1 (es) | 2006-01-18 |
| ES2341869T3 (es) | 2010-06-29 |
| JP2007517852A (ja) | 2007-07-05 |
| AU2005203972A1 (en) | 2005-07-21 |
| EP1701960B1 (de) | 2010-03-17 |
| TWI343384B (en) | 2011-06-11 |
| WO2005066180A9 (en) | 2008-09-25 |
| BRPI0506719A (pt) | 2007-05-02 |
| HK1096956A1 (en) | 2007-06-15 |
| CA2552739A1 (en) | 2005-07-21 |
| TW200536847A (en) | 2005-11-16 |
| DE602005019971D1 (de) | 2010-04-29 |
| EP1701960A1 (de) | 2006-09-20 |
| WO2005066180A1 (en) | 2005-07-21 |
| JP4787765B2 (ja) | 2011-10-05 |
| US7915300B2 (en) | 2011-03-29 |
| US20080234260A1 (en) | 2008-09-25 |
| AU2005203972B2 (en) | 2010-11-18 |
| US20110112089A1 (en) | 2011-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE461200T1 (de) | Inhibitoren von cysteinprotease | |
| ATE482214T1 (de) | Aspartylproteasehemmer | |
| ATE439835T1 (de) | Heterozyklische aspartyl-proteasehemmer | |
| ATE530554T1 (de) | Serinprotease-hemmer | |
| ATE478070T1 (de) | Heterozyklische aspartyl-proteasehemmer | |
| NO20044258L (no) | Cystein proteaseinhibitor | |
| EP1499336A4 (de) | Proteasehemmer | |
| PT1586571E (pt) | Inibidores da dipeptidil-peptidase | |
| DK1699455T3 (da) | Heterocykliske aspartylproteasehæmmere | |
| DK1924593T3 (da) | HCV NS3-proteaseinhibitorer | |
| NO20076678L (no) | Glutamataggrekanaseinhibitorer | |
| DE602005012267D1 (de) | N von geräten | |
| DE602004018837D1 (de) | Ptidase-iv-inhibitoren | |
| DK1817276T3 (da) | Cathepsin cysteine protease inhibitors | |
| DE502005005919D1 (de) | Alkoxysilanterminierte prepolymere | |
| EP1750696B1 (de) | Resistenzvermeidende inhibitoren für retrovirale proteasen | |
| EP1732891A4 (de) | Resistenzvermeidende inhibitoren für retrovirale proteasen | |
| ATE453699T1 (de) | Klebstoffe | |
| DK2067854T3 (da) | Kloningsvektorer | |
| ATE545642T1 (de) | Mmp-inhibitoren | |
| DE602005000066D1 (de) | Verdichter | |
| DK1645632T3 (da) | Alkalisk protease | |
| EP1767204A4 (de) | Lipase-inhibitoren | |
| DE602005002824T8 (de) | Kompressor | |
| ATE429417T1 (de) | Hiv-protease-inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |